MannKind: Cautiously Optimistic Ahead of AdCom Meeting 3/29/14

My latest thoughts on MannKind (MNKD – $4.83) ***The following is an excerpted and expanded upon selection from material published for subscribers of Nate’s Notes and The Wagmore Advisory Letter on 3/28/14*** After opening strong this morning following the release of the briefing documents associated with the upcoming FDA Advisory … Continue reading

MannKind (MNKD) – The Finish Line Is In Sight 3/16/14

Though I had hoped that we might get some news (or even just some dramatic price action in the stock) related to MannKind during the week last week that would have provided a springboard for an updated conversation and outlook, I am afraid it turned out to be a very … Continue reading